Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02496208
Title Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

urethra transitional cell carcinoma

Therapies

Ipilimumab

Cabozantinib + Nivolumab

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Comprehensive Cancer Center Duarte California 91010 United States Details
Los Angeles County-USC Medical Center Los Angeles California 90033 United States Details
USC / Norris Comprehensive Cancer Center Los Angeles California 90033 United States Details
University of California Davis Comprehensive Cancer Center Sacramento California 95817 United States Details
National Institutes of Health Clinical Center Bethesda Maryland 20892 United States Details
NCI - Center for Cancer Research Bethesda Maryland 20892 United States Details
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903 United States Details
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field